Navigation Links
VIB&CD3 enter into license and collaboration agreement with AstraZeneca for development of MALT1 inhibitor
Date:1/31/2014

cademic research of VIB with the strengths and capabilities of CD3 has been fruitful and resulted in this license and collaboration with AstraZeneca", said Patrick Chaltin, Managing Director of CD3 at KU Leuven. "This agreement again emphasizes the strength and value of CD3's model as an investment fund and technology transfer platform for innovative drug discovery."

"This collaboration is a further example of our ambition to increase innovation by bringing together the best of academia and AZ science. We are confident that these joint efforts will increase our understanding of MALT1 and its role in autoimmunity and oncology, with the aim of discovering and developing more effective patient treatments", says Maarten Kraan, Vice President, Respiratory, Inflammation & Autoimmunity Innovative Medicines and Early Development unit, AstraZeneca Mlndal.


'/>"/>

Contact: Kris Van der Beken
kris.vanderbeken@vib.be
32-473-783-435
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2

Related biology news :

1. UK establishes 3 new synthetic biology research centers
2. £3m drug safety center investment
3. FAK helps tumor cells enter the bloodstream
4. Museum bird DNA ready for use in Naturalis Biodiversity Center
5. Eurofins and Orion Diagnostica Oy enter into an agreement on Orions proprietary SIBA technology
6. Uganda Heart Institute physicians and nurses visit Texas Childrens Heart Center
7. Army renews bio-inspired engineering and science research center at UC Santa Barbara with $48 million
8. Data centers can be cooled down in environmentally friendly, energy efficient ways
9. DFG establishes 9 new collaborative research centers
10. Wilson Center awarded European Union grant for synthetic biology work
11. Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... N.H. Small streams play a significant role in ... by removing nitrogen before it ends up in estuaries ... the journal Nature. University of New Hampshire professor William ... department of natural resources, are among the co-authors of ...
... one of the worlds most endangered speciesa North Island brown ... been incubating the egg for five weeks, following a month ... signs of pipping: the process in which the chick starts ... isolet for four days and is now in a specially ...
... minimizing the amount of human-generated pollutants, such as nitrogen, ... excess nitrogen degrades lakes and coastal oceans by stimulating ... phenomenon, also known as eutrophication, threatens fisheries around the ... that included Cary Institute ecologists Dr. Stuart E.G. Findlay ...
Cached Biology News:Streams remove significant amounts of nitrogen, preventing downstream 'dead zones' 2Rare North Island brown kiwi hatches at the Smithsonian's National Zoo 2Small streams mitigate human influence on coastal ecosystems 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 6 Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today ... Business Development, will provide a company update at,the Rodman ... 2008 at 11:10 a.m. EST at the New York ... access the live webcast of the presentation by,visiting the ...
... PHOENIX, Nov. 6 NutraCea (OTC Bulletin Board:,NTRZ), ... nutrient research and,technology announced today that it has ... Financial Officer. Todd Crow, in accordance with,his previously ... remain,available in a consulting and advisory capacity., ...
... today at 5:00 p.m. Eastern to discuss ... recent business highlights -, SAN DIEGO, Calif., Nov. 6 ... focused on,the treatment of obesity and other central nervous system-related,disorders, ... ended September 30, 2008., Three Months Ended September 30, ...
Cached Biology Technology:NutraCea Appoints New Chief Financial Officer 2Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 9
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
... The Human Neural Stem Cell ... media supplements, which can be used ... expansion of NSCs and the induction ... oligodendrocyte lineages. An antibody panel consisting ...
Biology Products: